炎症性肠病(IBD)为消化系统难治性常见病，发病机制不明，缺乏良效低毒药。中药苦木广泛用于IBD治疗，其物质基础及作用机制缺乏系统研究。结合IBD研究新进展及前期基础，本项目提出“生物碱类成分为苦木干预IBD潜在的药效物质，其作用机制涉及调控肠道菌群失衡、宿主-肠菌代谢、炎症通路的多个环节和靶点”的科学假说。拟以经典的TNBS和DSS诱导结肠炎动物模型、 细胞模型（TNF-α孵育HCT116细胞），从整体动物、组织细胞及分子水平3个层面构建苦木抗IBD药效评价体系，以生物碱活性组分和/或成分对IBD作用的整体效应、炎症通路调控、肠道粘膜屏障修复、肠道微生态调控、宿主-肠菌代谢干预等层面，阐明苦木抗IBD的药效特点及作用机制；以活性组分和/或成分在正常及IBD病理状态下药代动力学及组织分布特征、血液移行成分、体内存在形式及经时变化，揭示苦木干预IBD药效物质。

Inflammatory bowel disease (IBD) is a common refractory disease of the digestive system. Ramulus et Folium Picrasmae，a traditional Chinese medicine commonly named as “kumu”, is widely used in the treatment of IBD. Combined with the new progress and preliminary basis of IBD research, this project proposed the scientific hypothesis that "alkaloid components are potential active components on IBD, and the mechanism of is involved in regulating multiple links and targets of intestinal flora imbalance, host-intestinal bacteria metabolism, and inflammatory signaling pathway". Therefore, the mechanism of alkaloid components from Ramulus et Folium Picrasmae on drug transportation, regulation for intestinal flora alteration, host-enterobacteria co-metabolism and inflammatory pathways will be investigated on basis of systematically compared studies between normal and pathologic status. The results are prospected to clarify the mechanisms for pharmacological and compatibility mechanisms of “kumu” for IBD, and apply scientific reference for its clinical application.